Skip to main content

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Research lines

Estudi de les bases biològiques de patologies glomerulars o sistèmiques amb directe afectació renal com la nefropatia diabètica, així com l'estudi dels diferents mediadors del Fracàs Renal Agut en el context de noxes diferent

IP: Maria Jose Soler Romeo, Concepció Jacobs Cachá

Projects

Creación de un método de referencia para detectar Apo-lb por espectrometría de masas dirigida y validación clínica de su potencial como biomarcadore para el síndrome nefrótico idiopático

IP: Concepció Jacobs Cachá
Collaborators: Laura Conesa Milian, Yolanda Villena Ortiz, Joan López Hellin, Carmen Llorens Cebriá, Juan Carlos León Román
Funding agency: Instituto de Salud Carlos III
Funding: 71250
Reference: PI24/01573
Duration: 01/01/2025 - 31/12/2027

ESTUDIO DE LA ENDOCITOSIS MEDIADA POR CUBILINA DE PROTEOFORMAS DE APOA-I EN ORGANOIDES RENALES HUMANOS

IP: Concepció Jacobs Cachá
Collaborators: Miriam Izquierdo Sans
Funding agency: Sociedad Española de Nefrología (S.E.N.)
Funding: 6000
Reference: SEN/AYUDAS OTROS CENTROS/2023/JACOBS
Duration: 01/09/2023 - 30/11/2023

Optimización del test de deposición ex vivo de C5b9 para monitorizar la actividad y la respuesta al tratamiento en SHUa y otras glomerulopatías complejas

IP: Concepció Jacobs Cachá
Collaborators: Manuel Hernández González, Natalia Ramos Terrades, Joana Sellarés Roig, Carmen Llorens Cebriá, Janire Perurena Prieto
Funding agency: Sociedad Española de Nefrología (S.E.N.)
Funding: 24000
Reference: SENEFRO/PROJECTES/2023/JACOBS
Duration: 23/12/2023 - 22/12/2025

Hacia un manejo clínico personalizado de pacientes oncológicos con fracaso renal agudo asociado a los immune-checkpoint inhibitors (ICIs)

IP: Maria Jose Soler Romeo
Collaborators: Oriol Bestard Matamoros, Sheila Bermejo Garcia, Concepció Jacobs Cachá, Elena Isabel Crespo Gimeno
Funding agency: Instituto de Salud Carlos III
Funding: 246840
Reference: AC22/00029
Duration: 01/01/2023 - 31/12/2025

Related news

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.

Related professionals

Tudela Trancoso, Miriam

Tudela Trancoso, Miriam

Shock, Organ Dysfunction and Resuscitation
Read more
Pons Prata, Judit

Pons Prata, Judit

Shock, Organ Dysfunction and Resuscitation
Read more
Alarcon Gimenez, Irene

Alarcon Gimenez, Irene

Clinical Neuroimmunology
Read more
Solé Fernandez, Mireia

Solé Fernandez, Mireia

Predoctoral researcher
Multidisciplinary Nursing Research Group
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.